NA Antiviral Drugs Market - Industry Trends and Forecast to 2030
North America antiviral drugs market is expected to reach USD 63,215.26 million by 2030 from USD 41,359.32 million in 2022, growing with a CAGR of 5.5% during the forecast period from 2023 to 2030.
Market Segmentation:
North America Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.
Overview of North America Antiviral Drugs Market Dynamics:
Driver
• Rising prevalence of viral infections
Restrain
• High cost of antiviral drugs
Opportunity
• Increasing collaboration and partnership among key players
Market Players:
Some of the key market players operating in the North America antiviral drugs market are listed below:
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• GLAXOSMITHKLINE PLC
• Abbvie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.
• Zydus Pharmaceuticals, Inc.
• Mylan Pharmaceuticals ULC
• Teva Pharmaceuticals USA, Inc.
• EMERGENT
• Sun Pharmaceutical Industries Ltd.
• Avet Pharmaceuticals Inc.
• Pfizer Inc.
• SIGA Technologies
• NAVINTA LLC.
• Macleods Pharmaceuticals Ltd.
• BioCryst Pharmaceuticals, Inc
• Hetero
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
- 1 Introduction 119
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of The North America Antiviral Drugs Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation 127
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Product Type Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market Testing Type Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary 139
- 4 Premium Insights 142
- 4.1 Porter’s Five Forces
- 4.2 Pestel Analysis
- 5 Epidemiology 145
- 6 Pipeline Analysis For North America Antiviral Drugs Market 146
- 7 Regulatory Framework 147
- 8 Market Overview 149
- 8.1 Drivers
- 8.1.1 Rising Prevalence Of Viral Infections
- 8.1.2 Advancements In New Antiviral Drug Development
- 8.1.3 Growing Demand For Combination Therapies
- 8.1.4 Increasing Government Funding And R&D Activities
- 8.2 Restrains
- 8.2.1 High Cost Of Antiviral Drugs
- 8.2.2 Emergence Of Drug-resistant Strains Of Viruses
- 8.3 Opportunities
- 8.3.1 Increasing Collaboration And Partnership Among Key Players
- 8.3.2 Rising Novel Drug Delivery Systems
- 8.3.3 Development Of Personalized Medicines
- 8.4 Challenges
- 8.4.1 Patent Expiration Of Antiviral Drugs
- 8.4.2 Demand For Alternative Medicines
- 9 North America Antiviral Drugs Market, By Indication 159
- 9.1 Overview
- 9.2 Influenza
- 9.2.1 Neuraminidase Inhibitors
- 9.2.1.1 Oseltamivir
- 9.2.1.2 Zanamivir
- 9.2.1.3 Peramivir
- 9.2.1.4 Laninamivir
- 9.2.2 M2 Inhibitors
- 9.2.2.1 Rimantadine
- 9.2.2.2 Others
- 9.2.3 Rna Polymerase Inhibitors
- 9.2.3.1 Favipiravir
- 9.2.3.2 Baloxavir Marboxil
- 9.3 Human Immunodeficiency Virus (Hiv)
- 9.3.1 Reverse Transcriptase Inhibitors
- 9.3.1.1 Nucleoside (Nrtis)
- 9.3.1.1.1 Lamivudine
- 9.3.1.1.2 Abacavir
- 9.3.1.1.3 Didanosine
- 9.3.1.1.4 Others
- 9.3.1.2 Nonnucleoside (Nnrtis)
- 9.3.1.2.1 Efavirenz
- 9.3.1.2.2 Nevirapine
- 9.3.1.2.3 Delavirdine
- 9.3.1.2.4 Others
- 9.3.1.3 Integrase
- 9.3.1.3.1 Dolutegravir
- 9.3.1.3.2 Elvitegravir
- 9.3.1.3.3 Raltegravir
- 9.3.1.3.4 Bictegravir
- 9.3.1.4 Nucleotide
- 9.3.1.4.1 Tenofovir
- 9.3.1.4.2 Others
- 9.3.1.5 Interferons
- 9.3.1.5.1 Alpha
- 9.3.1.5.2 Beta
- 9.3.1.5.3 Gamma
- 9.3.1.6 Gp41
- 9.3.1.6.1 Enfuvirtide
- 9.3.1.6.2 Others
- 9.3.2 Protease
- 9.3.2.1 Atazanavir
- 9.3.2.2 Darunavir
- 9.3.2.3 Lopinavir
- 9.3.2.4 Ritonavir
- 9.3.2.5 Saquinavir
- 9.3.2.6 Indinavir
- 9.3.2.7 Nelfinavir
- 9.3.2.8 Tipranavir
- 9.3.2.9 Amprenavir
- 9.4 Hepatitis C Virus
- 9.4.1 Ns5b Polymerase
- 9.4.1.1 Sofosbuvir
- 9.4.1.2 Dasabuvir
- 9.4.2 Ns3/4a Protease
- 9.4.2.1 Danoprevir
- 9.4.2.2 Glecaprevir
- 9.4.2.3 Grazoprevir
- 9.4.2.4 Paritaprevir
- 9.4.2.5 Simeprevir
- 9.4.3 Ns5a Phosphoprotein
- 9.4.3.1 Ledipasvir
- 9.4.3.2 Velpatasvir
- 9.4.3.3 Ombitasvir
- 9.4.3.4 Elbasvir
- 9.4.3.5 Daclatasvir
- 9.4.3.6 Pibrentasvir
- 9.4.4 Neuraminidase
- 9.4.4.1 Oseltamivir
- 9.4.4.2 Zanamivir
- 9.4.4.3 Peramivir
- 9.4.4.4 Laninamivir
- 9.4.5 Rna Polymerase
- 9.4.5.1 Baloxavir Marboxil
- 9.4.5.2 Favipiravir
- 9.4.6 Matrix Protein 2
- 9.4.6.1 Rimatidine
- 9.4.6.2 Favipiravir
- 9.5 Herpes Simplex Virus
- 9.5.1 Dna Polymerase Ul30
- 9.5.1.1 Aciclovir
- 9.5.1.2 Famciclovir
- 9.5.1.3 Valaciclovir
- 9.5.1.4 Penciclovir Trifluridine
- 9.5.1.5 Brivudine
- 9.5.1.6 Foscarnet
- 9.5.1.7 Idoxuridine
- 9.5.2 Envelope Proteins
- 9.5.2.1 Docosanol
- 9.5.2.2 Others
- 9.6 Human Cytomegalovirus (Hcmv)
- 9.6.1 Ganciclovir
- 9.6.2 Valganciclovir
- 9.6.3 Cidofovir
- 9.6.4 Foscarnet
- 9.6.5 Fomivirsen
- 9.7 Varicella-zoster Virus (Vzv)
- 9.7.1 Valaciclovir
- 9.7.2 Famciclovir
- 9.7.3 Aciclovir
- 9.7.4 Vidarabine
- 9.7.5 Brivudine
- 9.8 Hepatitis B Virus
- 9.8.1 Entecavir
- 9.8.2 Tenofovir
- 9.8.3 Telbivudine
- 9.8.4 Tenofovir Alafenamide
- 9.8.5 Others
- 9.9 Respiratory Syncytial Virus
- 9.9.1 Rna Polymerase
- 9.9.1.1 Ribavirin
- 9.9.1.2 Others
- 9.9.2 Fusion Glycoprotein
- 9.9.2.1 Palivizumab
- 9.9.2.2 Others
- 9.10 Coronavirus Infection
- 9.11 Others
- 10 North America Antiviral Drugs Market, By Patient Type 190
- 10.1 Overview
- 10.2 Geriatric
- 10.2.1 Male
- 10.2.2 Female
- 10.3 Child
- 10.3.1 Male
- 10.3.2 Female
- 10.4 Adult
- 10.4.1 Male
- 10.4.2 Female
- 11 North America Antiviral Drugs Market, By Products 198
- 11.1 Overview
- 11.2 Oral
- 11.2.1 Solid
- 11.2.1.1 Tablets
- 11.2.1.2 Capsules
- 11.2.1.3 Others
- 11.2.2 Semisolid
- 11.2.2.1 Gels
- 11.2.2.2 Emulsions
- 11.2.2.3 Elixirs
- 11.2.2.4 Others
- 11.2.3 Liquid
- 11.2.3.1 Solutions
- 11.2.3.2 Syrups
- 11.2.3.3 Others
- 11.3 Topical
- 11.3.1 Semi-solid
- 11.3.1.1 Cream
- 11.3.1.2 Ointment
- 11.3.1.3 Gels
- 11.3.1.4 Others
- 11.3.2 Liquid
- 11.3.2.1 Solutions
- 11.3.2.2 Suspensions
- 11.3.3 Solid
- 11.3.3.1 Powders
- 11.3.3.2 Suppositories
- 11.3.3.3 Enema
- 11.3.3.4 Others
- 11.4 Parenteral
- 11.4.1 Conventional Drug Delivery Formualtions
- 11.4.1.1 Solutions
- 11.4.1.2 Reconstituted/Lyophilized
- 11.4.1.3 Suspensions
- 11.4.1.4 Emulsions
- 11.4.1.5 Others
- 11.4.2 Novel Drug Delivery Formulations
- 11.4.3 Colloidal Dispersions
- 11.4.4 Long Acting Injection Formulation
- 12 North America Antiviral Drugs Market, By Drug Type 211
- 12.1 Overview
- 12.2 Generic
- 12.3 Branded
- 13 North America Antiviral Drugs Market, By End User 216
- 13.1 Overview
- 13.2 Hospital
- 13.3 Specialty Centers
- 13.4 Ambulatory Centres
- 13.5 Clinics
- 13.6 Home Healthcare
- 13.7 Others
- 14 North America Antiviral Drugs Market, By Distribution Channel 223
- 14.1 Overview
- 14.2 Hospital Pharmacy
- 14.3 Retail Pharmacy
- 14.4 Online Pharmacy
- 15 North America Antiviral Drugs Market, By Region 229
- 15.1 North America
- 15.1.1 U.S.
- 15.1.2 Canada
- 15.1.3 Mexico
- 16 North America Antiviral Drugs Market: Company Landscape 307
- 16.1 Company Share Analysis: North America
- 17 Swot Analysis 308
- 18 Company Profile 309
- 18.1 Gilead Sciences, Inc. (2022)
- 18.1.1 Company Snapshot
- 18.1.2 Revenue Analysis
- 18.1.3 Company Share Analysis
- 18.1.4 Product Portfolio
- 18.1.5 Recent Development
- 18.2 Pfizer Inc. (2022)
- 18.2.1 Company Snapshot
- 18.2.2 Revenue Analysis
- 18.2.3 Company Share Analysis
- 18.2.4 Product Portfolio
- 18.2.5 Recent Developments
- List Of Tables
- Table 1 North America Antiviral Drugs Market, By Indication, 2021- 2030 (Usd Million)
- Table 2 North America Influenza In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 3 North America Influenza In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 4 North America Neuraminidase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 5 North America M2 Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 6 North America M2 Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 7 North America Human Immunodeficiency Virus (Hiv) In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 8 North America Human Immunodeficiency Virus (Hiv) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 9 North America Reverse Transcriptase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 10 North America Nucleoside (Nrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 11 North America Nonnucleoside (Nnrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 12 North America Integrase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 13 North America Nucleotide In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 14 North America Interferons In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 15 North America Gp41 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 16 North America Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 17 North America Hepatitis C Virus In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 18 North America Hepatitis C Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 19 North America Ns5b Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 20 North America Ns3/4a Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 21 North America Ns5a Phosphoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 22 North America Neuraminidase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 23 North America Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 24 North America Matrix Protein 2 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 25 North America Herpes Simplex Virus In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 26 North America Herpes Simplex Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 27 North America Dna Polymerase Ul30 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 28 North America Envelope Proteins In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 29 North America Human Cytomegalovirus (Hcmv) In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 30 North America Human Cytomegalovirus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 31 North America Varicella-zoster Virus (Vzv) In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 32 North America Dna Polymerase Adefovir In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 33 North America Hepatitis B Virus In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 34 North America Dna Polymerase Adefovir In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 35 North America Respiratory Syncytial Virus In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 36 North America Respiratory Syncytical Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 37 North America Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 38 North America Fusion Glycoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 39 North America Coronavirus Infection In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 40 North America Others In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 41 North America Antiviral Drugs Market, By Patient Type, 2021- 2030 (Usd Million)
- Table 42 North America Geriatric In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 43 North America Geriatric In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 44 North America Child In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 45 North America Child In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 46 North America Adult In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 47 North America Adult In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 48 North America Antiviral Drugs Market, By Product, 2021- 2030 (Usd Million)
- Table 49 North America Oral In Antiviral Drugs Market, By Region, 2021-2030 (Usd Million)
- Table 50 North America Oral In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 51 North America Solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 52 North America Semi-solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 53 North America Liquid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 54 North America Topical In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 55 North America Topical In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 56 North America Semi-solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 57 North America Liquid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 58 North America Solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 59 North America Parenteral In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 60 North America Parenteral In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 61 North America Conventional Drug Delivery Formulations In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 62 North America Novel Drug Delivery Formulations In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 63 North America Antiviral Drugs Market, By Drug Type, 2021- 2030 (Usd Million)
- Table 64 North America Antiviral Drugs Market, By End User, 2021- 2030 (Usd Million)
- Table 65 North America Antiviral Drugs Market, By Distribution Channel, 2021- 2030 (Usd Million)
- Table 66 North America Antiviral Drugs Market, By Country, 2021-2030 (Usd Million)
- Table 67 North America Antiviral Drugs Market, By Indication, 2021-2030 (Usd Million)
- Table 68 North America Influenza In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 69 North America Neuraminidase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 70 North America M2 Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 71 North America Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 72 North America Human Immunodeficiency Virus (Hiv) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 73 North America Reverse Transcriptase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 74 North America Nucleoside (Nrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 75 North America Nonnucleoside (Nnrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 76 North America Integrase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 77 North America Nucleotide In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 78 North America Interferons In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 79 North America Gp41 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 80 North America Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 81 North America Hepatitis C Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 82 North America Ns5b Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 83 North America Ns3/4a Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 84 North America Ns5a Phosphoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 85 North America Neuraminidase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 86 North America Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 87 North America Matrix Protein 2 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 88 North America Herpes Simplex Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 89 North America Dna Polymerase Ul30 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 90 North America Envelope Proteins In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 91 North America Human Cytomegalovirus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 92 North America Varicella-zoster Virus (Vzv) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 93 North America Dna Polymerase Adefovir In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 94 North America Respiratory Syncytical Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 95 North America Respiratory Syncytical Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 96 North America Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 97 North America Fusion Glycoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 98 North America Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 99 North America Geriatric In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 100 North America Child In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 101 North America Adult In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 102 North America Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 103 North America Oral In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 104 North America Solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 105 North America Semi-solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 106 North America Liquid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 107 North America Topical In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 108 North America Semi-solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 109 North America Liquid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 110 North America Solid In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 111 North America Parenteral In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 112 North America Conventional Drug Delivery Formulations In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 113 North America Novel Drug Delivery Formulations In Antiviral Drugs Market, By Products, 2021-2030 (Usd Million)
- Table 114 North America Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 115 North America Antiviral Drugs Market, By End User, 2021-2030 (Usd Million)
- Table 116 North America Antiviral Drugs Market, By Distribution Channel, 2021-2030 (Usd Million)
- Table 117 U.S. Antiviral Drugs Market, By Indication, 2021-2030 (Usd Million)
- Table 118 U.S. Influenza In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 119 U.S. Neuraminidase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 120 U.S. M2 Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 121 U.S. Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 122 U.S. Human Immunodeficiency Virus (Hiv) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 123 U.S. Reverse Transcriptase Inhibitors In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 124 U.S. Nucleoside (Nrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 125 U.S. Nonnucleoside (Nnrtis) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 126 U.S. Integrase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 127 U.S. Nucleotide In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 128 U.S. Interferons In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 129 U.S. Gp41 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 130 U.S. Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 131 U.S. Hepatitis C Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 132 U.S. Ns5b Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 133 U.S. Ns3/4a Protease In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 134 U.S. Ns5a Phosphoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 135 U.S. Neuraminidase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 136 U.S. Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 137 U.S. Matrix Protein 2 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 138 U.S. Herpes Simplex Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 139 U.S. Dna Polymerase Ul30 In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 140 U.S. Envelope Proteins In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 141 U.S. Human Cytomegalovirus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 142 U.S. Varicella-zoster Virus (Vzv) In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 143 U.S. Dna Polymerase Adefovir In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 144 U.S. Respiratory Syncytical Virus In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 145 U.S. Rna Polymerase In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 146 U.S. Fusion Glycoprotein In Antiviral Drugs Market, By Drug Type, 2021-2030 (Usd Million)
- Table 147 U.S. Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 148 U.S. Geriatric In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- Table 149 U.S. Child In Antiviral Drugs Market, By Patient Type, 2021-2030 (Usd Million)
- List Of Figures
- Figure 1 North America Antiviral Drugs: Segmentation
- Figure 2 North America Antiviral Drugs Market: Data Triangulation
- Figure 3 North America Antiviral Drugs Market: Droc Analysis
- Figure 4 North America Antiviral Drugs Market: North America Vs Regional Market Analysis
- Figure 5 North America Antiviral Drugs Market: Company Research Analysis
- Figure 6 North America Antiviral Drugs Market: Interview Demographics
- Figure 7 North America Antiviral Drugs Market: Dbmr Market Position Grid
- Figure 8 North America Antiviral Drugs Market: Market Testing Type Coverage Grid
- Figure 9 North America Antiviral Drugs Market: Vendor Share Analysis
- Figure 10 North America Antiviral Drugs Market: Segmentation
- Figure 11 The Rising Prevalence Of Viral Infections Is Expected To Drive The North America Antiviral Drugs Market In The Forecast Period
- Figure 12 The Influenza Segment Is Expected To Account For The Largest Share Of The North America Antiviral Drugs Market In 2023 & 2030
- Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The North America Antiviral Drugs Market
- Figure 14 North America Antiviral Drugs Market: By Indication , 2022
- Figure 15 North America Antiviral Drugs Market: By Indication , 2023-2030 (Usd Million)
- Figure 16 North America Antiviral Drugs Market: By Indication , Cagr (2023-2030)
- Figure 17 North America Antiviral Drugs Market: By Indication , Lifeline Curve
- Figure 18 North America Antiviral Drugs Market: By Patient Type, 2022
- Figure 19 North America Antiviral Drugs Market: By Patient Type, 2023-2030 (Usd Million)
- Figure 20 North America Antiviral Drugs Market: By Patient Type, Cagr (2023-2030)
- Figure 21 North America Antiviral Drugs Market: By Patient Type, Lifeline Curve
- Figure 22 North America Antiviral Drugs Market: By Product, 2022
- Figure 23 North America Antiviral Drugs Market: By Product, 2023-2030 (Usd Million)
- Figure 24 North America Antiviral Drugs Market: By Product, Cagr (2023-2030)
- Figure 25 North America Antiviral Drugs Market: By Product, Lifeline Curve
- Figure 26 North America Antiviral Drugs Market: By Drug Type, 2022
- Figure 27 North America Antiviral Drugs Market: By Drug Type, 2023-2030 (Usd Million)
- Figure 28 North America Antiviral Drugs Market: By Drug Type, Cagr (2023-2030)
- Figure 29 North America Antiviral Drugs Market: By Drug Type, Lifeline Curve
- Figure 30 North America Antiviral Drugs Market: By End User, 2022
- Figure 31 North America Antiviral Drugs Market: By End User, 2023-2030 (Usd Million)
- Figure 32 North America Antiviral Drugs Market: By End User, Cagr (2023-2030)
- Figure 33 North America Antiviral Drugs Market: By End User, Lifeline Curve
- Figure 34 North America Antiviral Drugs Market: By Distribution Channel, 2022
- Figure 35 North America Antiviral Drugs Market: By Distribution Channel, 2023-2030 (Usd Million)
- Figure 36 North America Antiviral Drugs Market: By Distribution Channel, Cagr (2023-2030)
- Figure 37 North America Antiviral Drugs Market: By Distribution Channel, Lifeline Curve
- Figure 38 North America Antiviral Drugs Market: Snapshot (2022)
- Figure 39 North America Antiviral Drugs Market: By Country (2022)
- Figure 40 North America Antiviral Drugs Market: By Country (2023 & 2030)
- Figure 41 North America Antiviral Drugs Market: By Country (2022 & 2030)
- Figure 42 North America Antiviral Drugs Market: By Indication (2023-2030)
- Figure 43 North America Antiviral Drugs Market: Company Share 2022 (%) 216
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook